064ec215-7600-4e5d-be51-e757284f3e54
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.520
- E2F_TARGETS+0.440
- G2M_CHECKPOINT+0.360
- MYC_TARGETS_V1+0.360
- MTORC1_SIGNALING+0.240
- MITOTIC_SPINDLE+0.210
- CHOLESTEROL_HOMEOSTASIS+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- DNA_REPAIR+0.170
- HEDGEHOG_SIGNALING+0.160
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.580
- INTERFERON_ALPHA_RESPONSE-0.540
- ALLOGRAFT_REJECTION-0.520
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.500
- COMPLEMENT-0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- COAGULATION-0.440
- IL2_STAT5_SIGNALING-0.380
- KRAS_SIGNALING_UP-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-8352-01A-31R-2326-07 | — | cohortMD1 | 0.916 |
| 2 | SRR12696755 | — | — | 0.913 |
| 3 | TCGA-56-7730-01A-11R-2125-07 | — | cohortSQ2 | 0.912 |
| 4 | MNG392 | — | — | 0.910 |
| 5 | TCGA-J1-A4AH-01A-31R-A24H-07 | — | cohortSQ2 | 0.908 |
| 6 | SRR6013537 | — | cohortA3 | 0.905 |
| 7 | TCGA-AN-A0AR-01A-11R-A00Z-07 | — | E | 0.903 |
| 8 | SRR8518365 | — | E | 0.902 |
| 9 | BS_8SKZ7BRN | low-grade glioma | — | 0.901 |
| 10 | TCGA-66-2793-01A-01R-1201-07 | — | cohortMD1 | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.010 | Temsirolimus | — uncovered |